Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -4.63M | -13.67M | -15.18M | -15.35M | -12.08M |
| Total Depreciation and Amortization | 105.90K | 100.60K | 95.90K | 90.70K | 84.10K |
| Total Amortization of Deferred Charges | 348.80K | 299.80K | 207.60K | 126.90K | 56.20K |
| Total Other Non-Cash Items | -637.40K | -706.90K | 769.30K | 795.60K | 876.80K |
| Change in Net Operating Assets | 3.49M | 5.82M | 5.12M | 5.05M | 1.62M |
| Cash from Operations | -1.32M | -8.15M | -8.99M | -9.28M | -9.44M |
| Capital Expenditure | -29.50K | -36.10K | -63.00K | -67.50K | -71.10K |
| Sale of Property, Plant, and Equipment | 300.00 | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -226.10K | -275.40K | -327.30K | -340.30K | -391.00K |
| Cash from Investing | -255.30K | -311.50K | -390.30K | -407.70K | -462.00K |
| Total Debt Issued | 1.30M | 2.50M | 2.50M | 2.50M | 1.50M |
| Total Debt Repaid | -769.70K | -379.20K | -518.20K | -565.80K | -565.80K |
| Issuance of Common Stock | 643.80K | 0.00 | 0.00 | 2.20K | 2.20K |
| Repurchase of Common Stock | -- | -- | -- | -17.40K | -17.40K |
| Issuance of Preferred Stock | 7.27M | 6.17M | 6.17M | 6.17M | 2.21M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.05M | -1.01M | -1.01M | -977.90K | -14.60K |
| Cash from Financing | 7.39M | 7.28M | 7.14M | 7.11M | 3.11M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.82M | -1.18M | -2.24M | -2.58M | -6.79M |